Yoshikane Kikushige

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications

Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.

Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.

Journal: Cancer medicine
Published: March 20, 2026

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML.

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML.

Journal: Cancer science
Published: March 09, 2026

Early prediction of ICANS using CRS characteristics in B-cell lymphoma patients receiving CAR-T therapy.

Early prediction of ICANS using CRS characteristics in B-cell lymphoma patients receiving CAR-T therapy.

Journal: International journal of hematology
Published: February 25, 2026

Gilteritinib response in acute myeloid leukemia harboring a rare FLT3 juxtamembrane domain mutation with subsequent clonal evolution.

Gilteritinib response in acute myeloid leukemia harboring a rare FLT3 juxtamembrane domain mutation with subsequent clonal evolution.

Journal: Annals of hematology
Published: January 29, 2026

Frontline ATRA-ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG-APL2017 Trial.

Frontline ATRA-ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG-APL2017 Trial.

Journal: Cancer science
Published: October 12, 2025

Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL.

Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL.

Journal: International journal of hematology
Published: August 01, 2025

Comparison of quantitative PCR values and antigenemia for CMV monitoring in hematopoietic cell transplant recipients.

Comparison of quantitative PCR values and antigenemia for CMV monitoring in hematopoietic cell transplant recipients.

Journal: International journal of hematology
Published: July 02, 2025

Engraftment syndrome after PD-1 blockade in classical Hodgkin lymphoma treated by autologous stem cell transplantation.

Engraftment syndrome after PD-1 blockade in classical Hodgkin lymphoma treated by autologous stem cell transplantation.

Journal: International journal of hematology
Published: June 22, 2025

Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.

Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.

Journal: Blood
Published: June 04, 2025

Objective quantification of pre-CAR-T EEG abnormalities for ICANS prognosis: insights from GTE scoring.

Objective quantification of pre-CAR-T EEG abnormalities for ICANS prognosis: insights from GTE scoring.

Journal: Bone marrow transplantation
Published: February 22, 2025

Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.

Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.

Journal: International journal of hematology
Published: February 05, 2025

KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML.

KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML.

Journal: Leukemia
Published: January 30, 2025
Showing 1-12 of 74

Last Updated: 09/26/2026